Health Care & Life Sciences » Pharmaceuticals | Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
148.00
594.00
842.00
847
Gross Income
-
148.00
594.00
842.00
847
SG&A Expense
161.00
13,622.00
36,382.00
55,682.00
48,375
EBIT
161.00
13,770.00
36,976.00
56,524.00
49,222
Unusual Expense
-
17,600.00
-
-
-
Non Operating Income/Expense
-
-
601.00
861.00
2,283
Pretax Income
161.00
31,335.00
36,375.00
55,663.00
46,939
Consolidated Net Income
161.00
31,335.00
36,375.00
55,663.00
46,939
Net Income
161.00
31,335.00
36,375.00
55,663.00
46,939
Net Income After Extraordinaries
161.00
31,335.00
36,375.00
55,663.00
46,939
Net Income Available to Common
161.00
31,335.00
36,375.00
55,663.00
46,939
EPS (Basic)
0.01
1.48
2.36
2.72
1.71
Basic Shares Outstanding
21,111.40
21,111.40
15,422.00
20,488.50
27,510
EPS (Diluted)
0.01
1.48
2.36
2.72
1.71
Diluted Shares Outstanding
21,111.40
21,111.40
15,422.00
20,488.50
27,510
EBITDA
161.00
13,622.00
36,382.00
55,682.00
48,375
Non-Operating Interest Income
-
35.00
-
-
-

About Corvus Pharmaceuticals

View Profile
Address
863 Mitten Road
Burlingame California 94010
United States
Employees -
Website http://www.corvuspharma.com
Updated 07/08/2019
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of small molecule and antibody agents that target crucial enzymes and proteins in the immune system to treat patients with cancer. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.